PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), a developer of 'D11B', an anti-cancer compound shown in early studies to inhibit the growth of difficult-to-treat brain cancer, announced that the Company has entered into a Letter of Intent (LOI) with Shanghai Medicilon, Inc. Founded in 2004, Shanghai Medicilon provides drug discovery contract research services to pharmaceutical and biotech companies around the world... 
More...
More...